

Cover Story
Free
By Alexandria Carolan
A sense of foreboding descended on Narjust Duma as she sat at a presentation on drug-induced toxicities. The year was 2018, Duma was a 31-year-old second-year fellow at Mayo Clinic, and her discomfort stemmed from something other than the subject matter discussed.
In Brief


Clinical Roundup
Drugs & Targets
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - In her own words: Rathmell reflects on her priorities and values—and encourages everyone to do the same
- Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health
- Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas - Ci4CC’s 23rd Cancer Center Summit to focus on accelerating oncology innovation through AI
- White House preliminary budget document provides no funds for highly impactful CDC cancer registries program